Residents and Fellows Research in Progress
Saturday, October 12, 2024
11:30 AM–01:00 PM
Abstract
Introduction:
Cardiometabolic comorbidities are highly prevalent in individuals with neuropsychiatric conditions, contributing to increased mortality risk. Vulnerable adults in long-term care (LTC) settings often face complex medication regimens, including polypharmacy for both psychiatric and non-psychiatric conditions. Despite the widespread use of pharmacist-led medication therapy management (MTM) across various healthcare settings, its application in LTC remains limited. In response, an MTM program was developed by an LTC pharmacy primarily serving individuals with disabilities residing in over 2,000 facilities in the greater Twin Cities area. Building on a successful pilot project involving 458 residents (resulting in 1152 interventions with a 79.3% prescriber acceptance rate of suggested interventions), this quality improvement project aims to assess the impact of MTM on cardiometabolic comorbidities in facility residents with neuropsychiatric conditions.
Research Question or Hypothesis:
Do MTM interventions improve medication outcomes for cardiometabolic comorbidities in facility residents with neuropsychiatric conditions?
Study Design:
Quality improvement project involving retrospective review followed by prospective intervention and evaluation.
Methods:
The project is structured in two phases: a retrospective chart review of >850 MTM visits performed by July 2024, followed by a prospective evaluation of ongoing MTM interventions after July 2024. The primary outcome of the retrospective phase is the number of identified drug therapy problems (DTP) associated with medications for cardiometabolic conditions (e.g., cardiovascular diseases, diabetes, kidney diseases, and liver diseases). Each DTP is reviewed independently by two MTM pharmacists and validated externally. DTPs are scored on a 1-7 scale based on clinical significance (i.e., 1=adherence support vs 7=prevention of a life-threatening situation). The acceptance rate of suggested interventions sent to prescribers is quantified. Additionally, the compliance to the Medicare Star Ratings adherence measures related to diabetes, hypertension (RAS-acting agents), and statin medications is assessed within this population, identifying areas for improvement. The prospective phase implements targeted interventions to address identified gaps.
Results:
Will be presented.
Conclusion:
Will be presented.
Presenting Author
Lusi Zhang PharmD, MHIUniversity of Minnesota
Authors
Zachary Borgen PharmD
Geritom Medical, Inc.
John Kastner PharmD
Geritom Medical, Inc.
Clarice Olson RPh
Geritom Medical, Inc.
Jason Wachtl PharmD
Geritom Medical, Inc.